Transfusion-Related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective
Author(s)
Marcella Rivas Oliz Gardel de Alemar, BSc1, Graziela Dalla Rosa Bernardino, MBA2, Marcela C. Antonio, PhD1, Tarciso Sellani, PhD1, Danielle Silva, MSc, PharmD1, Straus Tanaka, PharmD3.
1GSK, Rio de Janeiro, Brazil, 2GSK, São paulo, Brazil, 3GSK, São Paulo, Brazil.
1GSK, Rio de Janeiro, Brazil, 2GSK, São paulo, Brazil, 3GSK, São Paulo, Brazil.
OBJECTIVES: This study aims to estimate the cost and time burden for patients with myelofibrosis and anaemia treated with momelotinib (MMB), ruxolitinib (RUX) and best available therapy (BAT) from a Brazilian supplementary health perspective.
METHODS: Transfusion data from SIMPLIFY 1 and 2 trials were used to estimate the number of red blood cell transfusion (RBCT) and time burden per patient profile (JAKi naïve and JAKi experienced) for the intention-to-treat population. Costs of transfusion were calculated considering Brazilian hierarchical classification of medical procedures and scenarios of different reimbursement value per health management organizations (HMOs) were explored based on the literature data and using different inflation rate index.
RESULTS: Reductions in transfusions associated with MMB projected time and cost savings, irrespective of patient profile and type of HMOs. The average annual number of transfusions changed depending on the patient profile: JAKi-naïve patients, 5.16 MMB and 18.12 RUX; JAKi experienced, 13.80 MMB and 17.28 BAT. The annual RBCT cost for JAKi naive (MMB vs. RUX): R$11,018 (R$8.814-R$13.221) vs R$38,690 (R$30.952-R$46.429); for JAKi experienced (MMB vs. BAT): R$29,466 (R$23.573-35.360) vs R$36,896 (R$29.518-R$44.276). Savings with MMB were also found when considering different reimbursement values per HMOs ranging from R$8380 to R$13,821 (JAKi naive); and R$2250 to R$3711 (JAKi experienced). Using different inflation rates led to the same conclusions. The reductions in transfusions were also associated with annual time saving when using MMB: −27.58 hours (JAKi naïve) and −6.96 hours (JAKi experienced).
CONCLUSIONS: MMB presented substantial reductions in costs and time spent on transfusions compared with RUX irrespective of patient profile and HMO perspectives. This analysis can provide detailed economic data to support clinical decision making and efficient resource management, focusing on optimising anaemia management in patients with myelofibrosis.
METHODS: Transfusion data from SIMPLIFY 1 and 2 trials were used to estimate the number of red blood cell transfusion (RBCT) and time burden per patient profile (JAKi naïve and JAKi experienced) for the intention-to-treat population. Costs of transfusion were calculated considering Brazilian hierarchical classification of medical procedures and scenarios of different reimbursement value per health management organizations (HMOs) were explored based on the literature data and using different inflation rate index.
RESULTS: Reductions in transfusions associated with MMB projected time and cost savings, irrespective of patient profile and type of HMOs. The average annual number of transfusions changed depending on the patient profile: JAKi-naïve patients, 5.16 MMB and 18.12 RUX; JAKi experienced, 13.80 MMB and 17.28 BAT. The annual RBCT cost for JAKi naive (MMB vs. RUX): R$11,018 (R$8.814-R$13.221) vs R$38,690 (R$30.952-R$46.429); for JAKi experienced (MMB vs. BAT): R$29,466 (R$23.573-35.360) vs R$36,896 (R$29.518-R$44.276). Savings with MMB were also found when considering different reimbursement values per HMOs ranging from R$8380 to R$13,821 (JAKi naive); and R$2250 to R$3711 (JAKi experienced). Using different inflation rates led to the same conclusions. The reductions in transfusions were also associated with annual time saving when using MMB: −27.58 hours (JAKi naïve) and −6.96 hours (JAKi experienced).
CONCLUSIONS: MMB presented substantial reductions in costs and time spent on transfusions compared with RUX irrespective of patient profile and HMO perspectives. This analysis can provide detailed economic data to support clinical decision making and efficient resource management, focusing on optimising anaemia management in patients with myelofibrosis.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE733
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology